These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29607153)

  • 61. Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability.
    Montella M; Sabetta R; Ronchi A; De Sio M; Arcaniolo D; De Vita F; Tirino G; Caputo A; D'Antonio A; Fiorentino F; Facchini G; Lauro GD; Perdonà S; Ventriglia J; Aquino G; Feroce F; Borges Dos Reis R; Neder L; Brunelli M; Franco R; Zito Marino F
    Front Med (Lausanne); 2022; 9():874213. PubMed ID: 35592855
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Aligning digital CD8
    Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
    Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
    [TBL] [Abstract][Full Text] [Related]  

  • 64. PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
    Schulz GB; Todorova R; Braunschweig T; Rodler S; Volz Y; Eismann L; Pfitzinger P; Jokisch F; Buchner A; Stief C; Mayr D; Casuscelli J
    Urol Oncol; 2021 Oct; 39(10):734.e1-734.e10. PubMed ID: 34261585
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.
    Wu S; Shi X; Sun J; Liu Y; Luo Y; Liang Z; Wang J; Zeng X
    Oncotarget; 2017 Mar; 8(10):16421-16429. PubMed ID: 28145884
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Yoh K; Matsumoto S; Furuya N; Nishino K; Miyamoto S; Oizumi S; Okamoto N; Itani H; Kuyama S; Nakamura A; Nishi K; Fukuda I; Tsuta K; Hayashi Y; Motoi N; Ishii G; Goto K
    Lung Cancer; 2021 Sep; 159():128-134. PubMed ID: 34333203
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comprehensive Analysis and Clinical Implication of PD-L1 Expression Considering HPV Status in Oropharyngeal Squamous Cell Carcinoma.
    Jeong JY; Park TI; Ahn D
    Anticancer Res; 2020 Jul; 40(7):4001-4010. PubMed ID: 32620644
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients.
    Tseng JS; Yang TY; Wu CY; Ku WH; Chen KC; Hsu KH; Huang YH; Su KY; Yu SL; Chang GC
    J Immunother; 2018; 41(6):292-299. PubMed ID: 29683890
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA
    Kim HR; Cha YJ; Hong MH; Gandhi M; Levinson S; Jung I; Lee JG; Lee CY; Cho BC; Ha SJ; Shim HS
    Oncotarget; 2017 Oct; 8(50):87234-87243. PubMed ID: 29152077
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.
    Wang Z; Ying J; Xu J; Yuan P; Duan J; Bai H; Guo C; Li L; Yang Z; Wan R; Fei K; Zhao Z; Du X; Zhao J; Lv N; Wang J
    JAMA Netw Open; 2020 Oct; 3(10):e2013770. PubMed ID: 33017026
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer.
    Dong Z; Liu Y; Jiang T; Hou L; Wu F; Gao G; Li X; Zhao C; Wang Y; Yang S; Mao S; Liu Q; Li Y; Xu C; Wu C; Ren S; Zhou C; Zhang J; Hirsch FR
    J Cancer; 2020; 11(3):551-558. PubMed ID: 31942178
    [No Abstract]   [Full Text] [Related]  

  • 72. Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review.
    Koomen BM; Badrising SK; van den Heuvel MM; Willems SM
    Histopathology; 2020 May; 76(6):793-802. PubMed ID: 31793055
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
    Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.
    Scheel AH; Baenfer G; Baretton G; Dietel M; Diezko R; Henkel T; Heukamp LC; Jasani B; Jöhrens K; Kirchner T; Lasitschka F; Petersen I; Reu S; Schildhaus HU; Schirmacher P; Schwamborn K; Sommer U; Stoss O; Tiemann M; Warth A; Weichert W; Wolf J; Büttner R; Rüschoff J
    Histopathology; 2018 Feb; 72(3):449-459. PubMed ID: 28851100
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system.
    Schats KA; Van Vré EA; De Schepper S; Boeckx C; Schrijvers DM; Waelput W; Fransen E; Vanden Bempt I; Neyns B; De Meester I; Kockx MM
    Histopathology; 2017 Jan; 70(2):253-263. PubMed ID: 27496355
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
    Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study.
    Ricci C; Capizzi E; Giunchi F; Casolari L; Gelsomino F; Rihawi K; Natali F; Livi V; Trisolini R; Fiorentino M; Ardizzoni A
    Ther Adv Med Oncol; 2020; 12():1758835920954802. PubMed ID: 33299472
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma.
    García A; Recondo G; Greco M; de la Vega M; Perazzo F; Recondo G; Avagnina A; Denninghoff V
    Heliyon; 2020 Jun; 6(6):e04117. PubMed ID: 32514486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.